Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Korro Bio Inc KRRO

Healthcare Biotechnology
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single... see more

Recent & Breaking News (NDAQ:KRRO)

    Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

    GlobeNewswire 3 days ago

    Korro to Participate in Upcoming Investor Conferences

    GlobeNewswire 9 days ago

    Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

    GlobeNewswire August 28, 2024

    Korro to Participate in Upcoming September Investor and Scientific Conferences

    GlobeNewswire August 27, 2024

    Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

    GlobeNewswire August 13, 2024

    Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

    GlobeNewswire July 1, 2024

    Korro to Participate in Upcoming June Investor and Scientific Conferences

    GlobeNewswire May 30, 2024

    Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

    GlobeNewswire May 20, 2024

    Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

    GlobeNewswire May 14, 2024

    Korro Announces $70 Million Private Placement

    GlobeNewswire April 18, 2024

    Korro to Participate in Upcoming Investor Conferences

    GlobeNewswire April 1, 2024

    Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

    GlobeNewswire March 26, 2024

    Korro to Present at the TD Cowen 44th Annual Health Care Conference

    GlobeNewswire February 27, 2024

    Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

    GlobeNewswire January 18, 2024

    Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GlobeNewswire January 4, 2024

    Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

    GlobeNewswire December 7, 2023

    Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

    GlobeNewswire November 28, 2023